

PATENT

Serial No. 10/016,969

Amylin Docket No.: 0401-UTL-0

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:

AMYLIN PHARMACEUTICALS, INC.

Group Art Unit: 1646

Applicants: Richard R. Pittner, et al..

Examiner: Ruixiang Li

**Serial No.:** 10/016,969

Filed: December 14, 2001

Title: PEPTIDE YY AND PEPTIDE YY

AGONISTS FOR TREATMENT OF

**METOBOLIC DISORDERS** 

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

BOX AF Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In compliance with 37 C.F.R. §1.56, the articles listed and identified on the attached Form 1449 are being submitted herewith for consideration by the Examiner. A copy of each of the listed items is included herewith.

## CERTIFICATE OF MAILING (37 C.F.R. §1.10)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage in an envelope addressed to Box AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Name of Person Mailing Paper

9/22/03

Date of Deposit

Signature of Person Mailing Paper

**PATENT** 

Serial No. 10/016,969

Amylin Docket No.: 0401-UTL-0

The above references are being cited only in the interests of candor and without any admission that they constitute statutory prior art or contain matter which anticipates the invention or which would render the same obvious, either singly or in combination, to a person of ordinary skill in the art.

No fee is believed due with this submission, however the Commissioner is hereby authorized to charge any fees associated with this submission to Deposit Account No.010535.

Respectfully submitted,

AMYLIN PHARMACEUTICALS, INC.

Dated:  $\frac{9/22}{\alpha3}$ 

By: \_\_\_\_\_\_

Registration No.:44,830

Amylin Pharmaceuticals, Inc. 9373 Towne Centre Drive San Diego, California 92121

Telephone: (858) 552-2200 Facsimile: (858) 552-1936



PTO/SB/08A (10-01)
Approved for use through 10/31/2002. 0MB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid 0MB control number.

Substitute for form 1449A/PT0					
SUPPLEMENTAL FORM PTO-1449	Complete if Known				
	Application Number	10/016,969			
	Filing Date	Dec 14, 2001			
(use as many sheets as necessary)	First Named Inventor	Pittner, R.A.			
<i>,</i>	Art Unit	1646			
	Examiner Name	Ruixiang Li			
Sheet 1 of 2	Attorney Docket Number	0401-UTL-0			

		U	S. PATENT DOC	UMENTS	•
Examiner Initials *	Cite No.1	U.S. Patent Document  Number Kind Code <sup>2</sup> (if known)	Publication Date MMDDYYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		5,696,093		Tseng	

F	<u> </u>	Foreign Patent Document	ON PATENT DOCU		Pages, Columns,	П
Examiner Initials *	Cite No.	Country Code <sup>3</sup> Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Lines, Where Relevant Passages or Relevant Figures Appear	Т
		WO 03/026591 A2	4/3/2003	Imperial College		-
					<u> </u>	┢


	 ·		•	
Examiner		Date	 	
0:		Date		
Signature		Considered		
		Constanta	 	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&#</sup>x27;Applicant's unique citation designation number(optional). ¹See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. ¹Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¹For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ¹Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08A (10-01)
Approved for use through 10/31/2002. 0MB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid 0MB control number.

Substitute for form 1449A/PT0						
	SUPPLEM	ENTAL.		Complete if Known		
				Application Number	10/016,969	
FORM PTO-1449				Filing Date	Dec 14, 2001	
	(use as man	y sheets as neces	sary)	First Named Inventor	Pittner, R.A.	
	(	y ancess as needs		Art Unit	1646	
				Examiner Name	Ruixiang Li	
Sheet	2	of	2	Attorney Docket Number	0401-UTL-0	

	T	OTHER PRIOR ART -NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	
Examiner Initials *	Cite No.1	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		BATTERHAM et al. "Inhibition of Food Intake in Obese Subjects by Peptide YY <sub>3-36</sub> ," N Engl J Med 2003 349:941-8.	
		BATTERHAM et al. "Gut hormone PYY <sub>3-36</sub> physiologically inhibits food intake," Nature 2002 418:650-4.	
		GARLICKI et al. "Cholecystokinin receptors and vagal nerves in control of food intake in rats," Amer Physiol Soc 1990.	
		GOMEZ et al. "Intestinal peptide YY: ontogeny of gene expression in rat bowel and tropic actions on rat and mouse bowel," Amer Physiol Soc 1995.	
		IYENGAR et al. "Characterization of Neuropeptide Y-Induced Feeding in Mice: Do Y1-Y6 Receptor Subtypes Mediate Feeding?" J Pharm and Exp Therap. 1999 289(2):1031-40.	
		MORLEY, "An Approach to the Development of Drugs for Appetite Disorders," Neuropsycholiology 1989 21:22-30.	
		MORLEY, et al., "An Investigation of Tolerance to the Actions of Leptogenic and Anorexigenic Drugs in Mice," Life Sciences, 1987 41:2257-2165.	
		MORLEY et al. "Peptide YY (PYY), a potent orexigenic agent," Brain Research 1985 341:200-3.	

	<u> </u>			
Examiner		Date	·	
Signature		Considered		 •

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.